Patient enrollment finalized in the Phase II trial testing allogeneic adipose tissue-derived mesenchymal stromal/stem cells (ASCs) in Sjögren’s syndrome

Author

Jens Kastrup

MD, DMSc, FESC

Aqueous Deficient Dry Eye Disease, Sjögren’s syndrome is a serious autoimmune disease that can cause serious eye and vision problems due to reduced tear production.

The patient enrollment is now finalized in the randomized double-blind placebo-controlled phase II trial testing the safety and efficacy of direct injection of ASCs into the lacrimal gland in 40 patients with Sjögren’s syndrome.

The follow-up is currently ongoing, and the final results are expected early 2023.